Drugs / HYODEOXYCHOLIC_ACID
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01931241 | Jun 2013 → Jun 2015 | hyperlipidemia | AtheroNova Inc. | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYODEOXYCHOLIC_ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL272621 ↗ |
| Known as | .alpha.-hyodeoxycholic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL272621 ↗ |
| Known as | AHRO-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931241 ↗ |
| Known as | Hdca | ChEMBL registry synonym — accepted as the source's own label CHEMBL272621 ↗ |
| Known as | Hyodesoxycholic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL272621 ↗ |
| Known as | NSC-60672 | ChEMBL registry synonym — accepted as the source's own label CHEMBL272621 ↗ |
| Action | Activate | “LXR-alpha agonist” CHEMBL272621 ↗1“LXR-beta agonist” CHEMBL272621 ↗ |
| Modality | Small molecule | — CHEMBL272621 ↗ |
| Route | Oral | “Oral AHRO-001” NCT01931241 ↗ |
| Target | NR1H2 | “LXR-beta agonist” CHEMBL272621 ↗ |
| Target | NR1H3 | “LXR-alpha agonist” CHEMBL272621 ↗ |